Select your language

  • EN
  • FR

abionyx linkedin 1ff75abionyx twitter b3bc9

logo abionyx new21

  • Home
  • About
    • About
    • Abionyx
    • Management
    • Board of Directors
    • Specialized Committees
      • - Audit Committee
      • - Remuneration Committee
    • Scientific Advisory Board
  • Our Assets
    • Our Assets
    • CER 001
    • CER 002
    • CER 209
  • Indications
    • LCAT
    • Sepsis
    • COVID
  • Media
    • Media
    • Press releases
    • ABIONYX in the media
  • Investors
    • Investors
    • Regulated information
    • Shareholder meeting
    • Analyst Research
    • Abionyx on stock market
    • Investor Contacts
    • Financial Calendar

abionyx

  • Media
  • Press releases
  • ABIONYX in the media

ABIONYX in the media

2023/10/05 - 18:00 Contract Pharma - Abionyx Pharma Manufactures First Batch of CER-001 with Recombinant Human ApoA-I pdf
2023/19/01 - 09:57 Scrip - Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa pdf
2023/17/01 - 19:00 FierceBiotech - Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims www
2023/17/01 - 10:00 European Biotechnology - Abionyx Pharma announces success in fighting sepsis-triggered AKI pdf
2023/17/01 - 10:00 Clinical Trials Arena - Abionyx Pharma’s Phase IIa trial of CER-001 for AKI meets primary objective pdf
2023/17/01 - 10:00 The Pharma Letter - Abionyx bullish on acute kidney injury drug’s prospects pdf
2023/17/01 - 10:00 European Clinical Review - Potential treatment identified for septic patients pdf
  • Contact
  • Legal notice
  • Processing of personal data
  • Privacy policy
  • General purchase conditions
  • General terms and conditions for procurement of services
© 2025 Abionyx : A new generation biotech company
Back to top